Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 16/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 3/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.41 |
| ▸ | TPX2 | Q9ULW0 | 3/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26326485 | 0.91 | KIT (0.42) | ERN1KITAURKBPDGFRBKDR | |
| SCHEMBL26326481 | 0.85 | AURKB (0.46) | ERN1KITAURKBPDGFRBKDR | |
| SCHEMBL26326493 | 0.82 | KIT (0.47) | KITAURKBPDGFRBKDRAURKA | |
| SCHEMBL1354627 | 0.70 | AURKB (0.57) | KITAURKBPDGFRBKDRAURKA | |
| SCHEMBL24164546 | 0.69 | KIT (0.46) | KITAURKBPDGFRBKDRAURKA | |
| SCHEMBL24166208 | 0.69 | ERN1 (0.42) | ERN1AURKA | |
| SCHEMBL1536818 | 0.69 | KIT (0.45) | KITAURKBPDGFRBKDRAURKA | |
| SCHEMBL16793662 | 0.68 | KIT (0.52) | KITAURKBAURKAINCENPTPX2 | |
| SCHEMBL25941068 | 0.68 | AURKA (0.57) | KITAURKBAURKAINCENPTPX2 | |
| SCHEMBL24615534 | 0.67 | AURKA (0.56) | KITAURKBAURKAINCENPTPX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | ERN1 1877/4885KIT 1490/4885AURKB 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.